These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38949295)

  • 41. Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Rodriguez LA; Schmittdiel JA; Liu L; Macdonald BA; Balasubramanian S; Chai KP; Seo SI; Mukhtar N; Levin TR; Saxena V
    JAMA Netw Open; 2024 Jul; 7(7):e2421019. PubMed ID: 38990573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
    Jeong S; Oh YH; Ahn JC; Choi S; Park SJ; Kim HJ; Lee G; Son JS; Jang H; Lee DH; Sha M; Chen L; Kim W; Park SM
    Clin Mol Hepatol; 2024 Jul; 30(3):487-499. PubMed ID: 38711390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
    Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
    Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.
    Sato A; Oomori Y; Nakano R; Matsuura T
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202611
    [No Abstract]   [Full Text] [Related]  

  • 46. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Habitual use of glucosamine and adverse liver outcomes among patients with type 2 diabetes and MASLD.
    Shen Y; Wang Y; Lu J; Mo Y; Ma X; Hu G; Zhou J
    Liver Int; 2024 Sep; 44(9):2359-2367. PubMed ID: 38842441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic dysfunction-associated steatotic liver disease and its link to cancer.
    Kalligeros M; Henry L; Younossi ZM
    Metabolism; 2024 Nov; 160():156004. PubMed ID: 39182603
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular complications during delivery hospitalizations in patients with nonalcoholic fatty liver disease in pregnancy.
    Niu C; Zhang J; Khalid N; Zhu K; Syed T; Liu H; Okolo PI
    Eur J Gastroenterol Hepatol; 2024 Sep; 36(9):1141-1148. PubMed ID: 38874917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Younossi ZM; Kalligeros M; Henry L
    Clin Mol Hepatol; 2024 Aug; ():. PubMed ID: 39159948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma.
    Han J; Kuai W; Yang L; Tao X; Wang Y; Zeng M; Li Y; Mi Y; Zhang N; Lu W; Xu L
    Cancer Biol Med; 2024 May; 21(9):813-25. PubMed ID: 38712819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
    Chen YT; Chen TI; Yin SC; Huang CW; Huang JF; Lu SN; Yeh ML; Huang CF; Dai CY; Chen YW; Chuang WL; Yu ML; Lee MH
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1939-1949. PubMed ID: 38725327
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies.
    Yasin A; Nguyen M; Sidhu A; Majety P; Spitz J; Asgharpour A; Siddiqui MS; Sperling LS; Quyyumi AA; Mehta A
    Diabetes Res Clin Pract; 2024 May; 211():111650. PubMed ID: 38604447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sex difference in skeletal muscle mass in relation to metabolic dysfunction-associated steatotic liver disease: a propensity score matching study.
    Son DH; Kwon YJ; Lee JH
    J Nutr Health Aging; 2024 Jun; 28(6):100270. PubMed ID: 38833877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intervening on Metabolic Dysfunction-Associated Steatotic Liver Disease in Latino/a and Black Patients with Diabetes: A Feasibility Pilot.
    Alexopoulos AS; Danus S; Parish A; Olsen MK; Batch BC; Thacker CR; Moylan CA; Crowley MJ
    Diabetes Ther; 2024 Nov; 15(11):2417-2427. PubMed ID: 39276291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Kumar J; Mohsin S; Hasan M; Bilal AR; Ali KM; Umer A; Hadi DZM; Nandlal S; Kumar S
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102261. PubMed ID: 38070828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.